Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation - Summary - MDSpire

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation

  • By

  • Tilman Schneider-Hohendorf

  • Christian Wünsch

  • Simon Falk

  • Catarina Raposo

  • Florian Rubelt

  • Hamid Mirebrahim

  • Hosseinali Asgharian

  • Ulrich Schlecht

  • Daniel Mattox

  • Wenyu Zhou

  • Eva Dawin

  • Marc Pawlitzki

  • Sarah Lauks

  • Sven Jarius

  • Brigitte Wildemann

  • Joachim Havla

  • Tania Kümpfel

  • Miriam-Carolina Schrot

  • Marius Ringelstein

  • Markus Kraemer

  • Carolin Schwake

  • Thomas Schmitter

  • Ilya Ayzenberg

  • Katinka Fischer

  • Sven G Meuth

  • Orhan Aktas

  • Martin W Hümmert

  • Julian R Kretschmer

  • Corinna Trebst

  • Ilka Kleffner

  • Jennifer Massey

  • Paolo A Muraro

  • Haiyin Chen-Harris

  • Catharina C Gross

  • Luisa Klotz

  • Heinz Wiendl

  • Nicholas Schwab

  • July 18, 2024

  • 0 min

Share

Objective:

To evaluate the EBV-specific T-cell receptor beta chain (TRB) repertoire in multiple sclerosis (MS) patients, specifically comparing its specificity to other CNS diseases and assessing the impact of MS therapies on this repertoire.

Key Findings:
  • MS patients exhibited a broader MHC-I-restricted EBV-specific TRB repertoire compared to controls, highlighting the unique immune response in MS.
  • No other evaluated CNS diseases showed a similar broadened anti-EBV TRB repertoire, underscoring the specificity of the response in MS.
  • MS therapies like ocrelizumab, teriflunomide, and dimethyl fumarate reduced EBV-specific TRB sequence matches, indicating a potential therapeutic effect.
Interpretation:

The altered EBV-specific T-cell response appears to be specific to MS and is influenced by MS treatments that target EBV host cells or activated lymphocytes, suggesting a dynamic interaction.

Limitations:
  • The study did not analyze the TRB repertoire of patients with other viral infections, which could provide additional context.
  • Potential confounding factors in the patient cohorts, such as demographic differences and disease duration, were not fully addressed.
Conclusion:

The findings suggest a specific and dynamic EBV-related immune response in MS, which could inform future therapeutic strategies targeting EBV, emphasizing the need for tailored treatments.

Original Source(s)

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation

  • by Tilman Schneider-Hohendorf, Christian Wünsch, Simon Falk, Catarina Raposo, Florian Rubelt, Hamid Mirebrahim, Hosseinali Asgharian, Ulrich Schlecht, Daniel Mattox, Wenyu Zhou, Eva Dawin, Marc Pawlitzki, Sarah Lauks, Sven Jarius, Brigitte Wildemann, Joachim Havla, Tania Kümpfel, Miriam-Carolina Schrot, Marius Ringelstein, Markus Kraemer, Carolin Schwake, Thomas Schmitter, Ilya Ayzenberg, Katinka Fischer, Sven G Meuth, Orhan Aktas, Martin W Hümmert, Julian R Kretschmer, Corinna Trebst, Ilka Kleffner, Jennifer Massey, Paolo A Muraro, Haiyin Chen-Harris, Catharina C Gross, Luisa Klotz, Heinz Wiendl, Nicholas Schwab

  • July 18, 2024

Related Content

Kappa free light chain index in multiple sclerosis and other inflammatory CNS diseases: a pilot single-center study from Argentina

Physical disability, cognition, and depression as determinants of quality of life in multiple sclerosis: a cross-sectional study

Non-Linear Measures of Movement Variability in Multiple Sclerosis: A Clinical Narrative Review of Lyapunov Exponent and Entropy Applications in Balance and Gait